RARB

Across TCGA pan-cancer cohorts, RARB Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RARB data layer compared with 29 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher RARB Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RARB expression acts as an unfavorable survival marker, although some lineages such as STAD and BLCA show a favorable association.

CESC, LGG, and UCEC are the cancer types where RARB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	III,IV	0.230	0.668	.038	6	view →
LGG	DFS	Median	All	0.225	0.738	.014	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
STAD	DFS	Median	II,III,IV	1.000	0.365	.017	6	view →
BLCA	DFS	Median	II,III,IV	0.877	0.499	.036	6	view →
LUSC	OS	Median	All	0.180	0.659	.047	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RARB–CESC (OS)

Open the CESC breakdown →